Frank Schnütgen

Dr. Frank Schnütgen

Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
+2
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2003 in Nature Biotechnology
Verified
Journal Article
Closed access
Frank SchnütgenFrank Schnütgen
Frank Schnütgen
NDNathalie Doerflinger
Nathalie Doerflinger
CCCécile Calléja
Cécile Calléja
OWOlivia Wendling
Olivia Wendling
PCPierre Chambon
Pierre Chambon
NGNorbert B. Ghyselinck
Norbert B. Ghyselinck

12 September 2012 in Mammalian Genome
Verified
Journal Article
Open access
PDF file
ABAllan Bradley
Allan Bradley
KAKonstantinos Anastassiadis
Konstantinos Anastassiadis
AAAbdelkader Ayadi
Abdelkader Ayadi
JBJames F. Battey
James F. Battey
CBCindy Bell
Cindy Bell
WWWolfgang Wurst
Wolfgang Wurst
In 2007, the International Knockout Mouse Consortium (IKMC) made the ambitious promise to generate mutations in virtually every protein-coding gene of the mouse genome in a concerted worldwide action. Now, 5 years later, the IKMC members have developed high-throughput gene trapping and, in particular, gene-targeting pipelines and generated more than 17,400 mutant murine embryonic stem (ES) cell clones and more than 1,700 mutant mouse strains, most of them conditional. A common IKMC web portal (www.knockoutmouse.org) has been established, allowing easy access to this unparalleled biological resource. The IKMC materials considerably enhance functional gene annotation of the mammalian genome and will have a major impact on future biomedical research.

1 September 1994 in Development
Verified
Journal Article
Open access
PDF file
AKAndreas Kurtz
Andreas Kurtz
AZAndreas Zimmer
Andreas Zimmer
Frank SchnütgenFrank Schnütgen
Frank Schnütgen
GBGerold Brüning
Gerold Brüning
FSFriedrich Spener
Friedrich Spener
TMThomas Müller
Thomas Müller
Fatty acid binding proteins (FABPs) are a multigene family of small intracellular proteins that bind hydrophobic ligands. In this report we describe the cloning and expression pattern of a novel member of this gene family that is specifically expressed in the developing and adult nervous system and thus was designated brain (B)-FABP. B-FABP is closely related to heart (H)-FABP with 67% amino acid identity. B-FABP expression was first detected at mouse embryonic day 10 in neuroepithelial cells and its pattern correlates with early neuronal differentiation. Upon further development, B-FABP was confined to radial glial cells and immature astrocytes. B-FABP mRNA and protein were found in glial cells of the peripheral nervous system such as satellite cells of spinal and cranial ganglia and ensheathing cells of the olfactory nerve layer from as early as embryonic day 11 until adulthood. In the adult mouse brain, B-FABP was found in the glia limitans, in radial glial cells of the hippocampal dentate gyrus and Bergman glial cells. These findings suggest a function of B-FABP during neurogenesis or neuronal migration in the developing nervous system. The partially overlapping expression pattern with that of cellular retinoid binding proteins suggests that B-FABP is involved in the metabo-lism of a so far unknown hydrophobic ligand with potential morphogenic activity during CNS development.

1 December 2011 in Cell Stem Cell
Verified
Journal Article
Closed access
UEUlrich Elling
Ulrich Elling
JTJasmin Taubenschmid
Jasmin Taubenschmid
GWGerald Wirnsberger
Gerald Wirnsberger
RORonan O'MAlley
Ronan O'MAlley
SDSimon-Pierre Demers
Simon-Pierre Demers
JPJosef M Penninger
Josef M Penninger

31 July 2019 in Cells
Verified
Journal Article
Open access
PDF file
JKJohanna Kreitz
Johanna Kreitz
CSChristine Schönfeld
Christine Schönfeld
MSMarcel Seibert
Marcel Seibert
VSVerena Stolp
Verena Stolp
IAIslam Alshamleh
Islam Alshamleh
HSHubert Serve
Hubert Serve
Acute myeloid leukemia (AML) is one of the most common and life-threatening leukemias. A highly diverse and flexible metabolism contributes to the aggressiveness of the disease that is still difficult to treat. By using different sources of nutrients for energy and biomass supply, AML cells gain metabolic plasticity and rapidly outcompete normal hematopoietic cells. This review aims to decipher the diverse metabolic strategies and the underlying oncogenic and environmental changes that sustain continuous growth, mediate redox homeostasis and induce drug resistance in AML. We revisit Warburg’s hypothesis and illustrate the role of glucose as a provider of cellular building blocks rather than as a supplier of the tricarboxylic acid (TCA) cycle for energy production. We discuss how the diversity of fuels for the TCA cycle, including glutamine and fatty acids, contributes to the metabolic plasticity of the disease and highlight the roles of amino acids and lipids in AML metabolism. Furthermore, we point out the potential of the different metabolic effectors to be used as novel therapeutic targets.

3 May 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Frank SchnütgenFrank Schnütgen
Frank Schnütgen
SDSilke De-Zolt
Silke De-Zolt
PSPetra Van Sloun
Petra Van Sloun
MHMelanie Hollatz
Melanie Hollatz
TFThomas Floss
Thomas Floss
HMHarald von Melchner
Harald von Melchner
A type of retroviral gene trap vectors has been developed that can induce conditional mutations in most genes expressed in mouse embryonic stem (ES) cells. The vectors rely on directional site-specific recombination systems that can repair and reinduce gene trap mutations when activated in succession. After the gene traps are inserted into the mouse genome, genetic mutations can be produced at a particular time and place in somatic cells. In addition to their conditional features, the vectors create multipurpose alleles amenable to a wide range of postinsertional modifications. Here we have used these directional recombination vectors to assemble the largest library of ES cell lines with conditional mutations in single genes yet assembled, presently totaling 1,000 unique genes. The trapped ES cell lines, which can be ordered from the German Gene Trap Consortium, are freely available to the scientific community.